Related references
Note: Only part of the references are listed.Selumetinib in Children with Inoperable Plexiform Neurofibromas
Andrea M. Gross et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Trametinib Induces Neurofibroma Shrinkage and Enables Surgery
Pia Vaassen et al.
NEUROPEDIATRICS (2019)
Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)-associated plexiform neurofibroma: A phase I/IIa study.
Geoffrey Brian McCowage et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1
D. Gareth R. Evans et al.
CLINICAL CANCER RESEARCH (2017)
Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1
Elina Uusitalo et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Eva Dombi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Neuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation
Corina Anastasaki et al.
HUMAN MOLECULAR GENETICS (2014)
Growth behavior of plexiform neurofibromas after surgery
Rosa Nguyen et al.
GENETICS IN MEDICINE (2013)
Birth Incidence and Prevalence of Tumor-Prone Syndromes: Estimates From a UK Family Genetic Register Service
D. G. Evans et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2010)
Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas
A. Kim et al.
NEUROLOGY (2009)
Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1
Victor-F. Mautner et al.
NEURO-ONCOLOGY (2008)
The NF1 tumor suppressor critically regulates TSC2 and mTOR
CM Johannessen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors
B Dasgupta et al.
CANCER RESEARCH (2005)